Erschienen in:
01.04.2019 | Neuro-oncology (Y Umemura, Section Editor)
Evidence-Based Practice: Temozolomide Beyond Glioblastoma
verfasst von:
Jason Chua, Elizabeth Nafziger, Denise Leung
Erschienen in:
Current Oncology Reports
|
Ausgabe 4/2019
Einloggen, um Zugang zu erhalten
Abstract
Purpose of Review
Temozolomide is a first-line treatment for newly diagnosed glioblastoma. In this review, we will examine the use of temozolomide in other contexts for treating gliomas, including recurrent glioblastoma, glioblastoma in the elderly, diffuse low- and high-grade gliomas, non-diffuse gliomas, diffuse intrinsic pontine glioma (DIPG), ependymoma, pilocytic astrocytoma, and pleomorphic xanthoastrocytoma.
Recent Findings
Temozolomide improved survival in older patients with glioblastoma, anaplastic gliomas regardless of 1p/19q deletion status, and progressive ependymomas. Temozolomide afforded less toxicity and comparable efficacy to radiation in high-risk low-grade gliomas and to platinum-based chemotherapy in pediatric high-grade gliomas.
Summary
The success of temozolomide in promoting survival has expanded beyond glioblastoma to benefit patients with non-glioblastoma tumors. Identifying practical biomarkers for predicting temozolomide susceptibility, and establishing complementary agents for chemosensitizing tumors to temozolomide, will be key next steps for future success.